Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 ZeClinics Moves Headquarters to Almirall R&D Centre | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

ZeClinics Moves Headquarters to Almirall R&D Centre

ZeClinics will leverage Almirall's state-of-the-art technology facilities to accelerate drug discovery by providing high-throughput safety and efficacy screenings.

By: Anthony Vecchione

Almirall, a global biopharmaceutical company focused on skin health, entered into an agreement with ZeClinics, a Contract Research Organization (CRO) specialized in zebrafish, to be based at Almirall’s R&D centre.

Through the agreement, Almirall aims to transform its R&D centre in Sant Feliu de Llobregat, Spain, into a uniquely collaborative environment where researchers from biotech companies, start-ups, academia, and other scientist meet with Almirall’s team to enhance research success.

Under the agreement, ZeClinics will be able to leverage Almirall’s state-of-the-art R&D facilities to help advance its innovative pipeline and provide customized services to help their clients with disease modelling, target discovery and drug development.

The R&D centre has 7,400 square meters of fully equipped laboratories and production area.

ZeClinics’ mission is to accelerate research by challenging the discovery process, with a model that combines the advantages of zebrafish with lab automation and artificial intelligence.

“Our agreement with ZeClinics highlights our commitment to enabling scientific innovation that improves people’s lives,” said Karl Ziegelbauer, Almirall S.A.’s chief scientific officer. Through these collaborations with biotech companies and academia, and the opening of our R&D centre, we reinforce our objective to create a cutting-edge research ecosystem.”

Simone Calzolari, ZeClinics’ CEO said: “Being part of such an innovative research hub gives us the opportunity to establish synergies, both in terms of knowledge and advanced technologies. It is a unique opportunity for ZeClinics to continue growing and providing higher-quality science to our clients.”


Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics